Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bruised But Not Broken: Pharmaceutical-Biotech Industry Expects $16 Billion in 2007 Capital Projects, an Industrial Info News Alert.


SUGAR LAND, Texas -- Researched by Industrial Info Resources (Sugar Land, Texas). With just days left before 2006 slips into the history books, it will not be soon enough for Big Pharma. The industry is only too eager to close the door on a brutal year. Industry leviathan leviathan (lēvī`əthən), in the Bible, aquatic monster, presumably the crocodile, the whale, or a dragon. It was a symbol of evil to be ultimately defeated by the power of good.  Pfizer had hoped to begin 2007 on a high note, but instead found itself on its knees. The company was set to launch Torcetrapib, a new cholesterol drug that had analysts predicting annual profits of up to $15 billion. Of course, that changed when results of a large clinical trial, released earlier this month, showed that rather than curing people it actually increased the risk of their death. After investing an estimated $1 billion on developing a drug it cannot sell, the press had another go at the weary giant, already used to negative headlines that followed each announcement of yet another plant closure, a topic examined in greater depth in Industrial Info's recently released 2007 Pharmaceutical-Biotech Industry Forecast. Yet, the industry is far from terminal. A current roster of over $16 billion North American North American

named after North America.


North American blastomycosis
see North American blastomycosis.

North American cattle tick
see boophilusannulatus.
 capital and maintenance projects scheduled for kick off in 2007 attests to its continued longevity.

There is no question that the face of the industry is changing, however, that change does not equate e·quate  
v. e·quat·ed, e·quat·ing, e·quates

v.tr.
1. To make equal or equivalent.

2. To reduce to a standard or an average; equalize.

3.
 with lack of growth, it is more rather a maturing of the industry. Swapping roles, the Biotech bi·o·tech  
n. Informal
Biotechnology.


biotech
Noun

short for biotechnology

Noun 1.
 sector is reminiscent of the heady head·y  
adj. head·i·er, head·i·est
1.
a. Intoxicating or stupefying: heady liqueur.

b.
 days of Pharma, as it continues its massive capital investment program to build up capacity to accommodate a fat pipeline of new drugs. Pharma, while pulling back for now on North American grassroot plant construction, is investing heavily into bolstering its research and development of new products.

For more Pharmaceutical-Biotech Industry trends and analysis check out Industrial Info's new 2007 Pharmaceutical-Biotech Industry Forecast or contact Member Center at 1-800-762-3361.

Industrial Info Resources (IIR IIR - Infinite Impulse Response ) is a Marketing Information Service company that has been doing business for over 23 years. IIR is respected as the leader in providing comprehensive market intelligence pertaining per·tain  
intr.v. per·tained, per·tain·ing, per·tains
1. To have reference; relate: evidence that pertains to the accident.

2.
 to the industrial processing, heavy manufacturing, and energy-related industries throughout the world. For more information send inquiries to pharmabiogroup@industrialinfo.com or visit us at www.industrialinfo.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 11, 2006
Words:366
Previous Article:UnumProvident Wins 'Process Innovation Award' from Kinetic Information for Stellent Sarbanes-Oxley Solution Implementation.
Next Article:"Outlook Good" for 60th Anniversary of the Original Magic 8 Ball(R).
Topics:



Related Articles
Amgen Wins, ImClone Loses in FDA Approval Gamble, in an Advisory by Industrialinfo.com.
Wyeth-Lederle Invests Over $200 Million in North Carolina Vaccine Facility, in an Advisory by Industrialinfo.com.
Merck Goes Back to School with $100 Million Research Center in Boston, in an Advisory by Industrialinfo.com.
Biopure to Spend $120 Million for Biopharmaceutical Plant in South Carolina, in an Advisory by Industrialinfo.com.
Pharma Industry Offers Up a Bitter Pill as Plants Continue to Close Across North America, an Industrial Info News Alert.
Pharmaceutical-Biotech Mid-Year Review - a Special Segment of Industry Today on Industrialinfo.com Radio.
North American Pharmaceutical & Biotech Industry to Finish Construction of 62 New Plants in 2006, an Industrial Info News Alert.
Boehringer-Ingelheim Continues Aggressive $260 Million Expansion Program at Virginia Plant Site, an Industrial Info News Alert.
Market Shift Pushes Lilly to Abandon Construction of $325 Million Insulin Plant in Virginia, an Industrial Info News Alert.
Australia Announces R&D Tax Breaks at BIO 2007.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles